Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874 · View on ClinicalTrials.gov ↗
Study Summary
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG PHN-012
Study Locations (7)
Texas
- PHN-012-001 Site — Houston
- PHN-012-001 Site — San Antonio
District of Columbia
- PHN-012-001 Site — Washington D.C.
Massachusetts
- PHN-012-001 Site — Boston
North Carolina
- PHN-012-001 Site — Durham
Tennessee
- PHN-012-001 Site — Nashville
Virginia
- PHN-012-001 Site — Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2025-09-23 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07127874
The ClinicalTrials.gov registry entry for NCT07127874 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pheon Therapeutics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention — of which PHN-012 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07127874 reports 7 study locations spanning 6 distinct geographic areas — top geographies include Texas, District of Columbia, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07127874 about?
NCT07127874 is a clinical study titled "A Study of PHN-012 in Patients With Advanced Solid Tumors". This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
What is the current status of trial NCT07127874?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2025-09-23. Estimated completion is 2028-05.
What conditions does trial NCT07127874 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Advanced Solid Tumors, Advanced Cancer, Colon Cancer, Lung Cancer (NSCLC). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07127874?
The interventions under investigation include: PHN-012 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07127874?
This trial is sponsored by Pheon Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07127874 being conducted?
This trial has 7 study locations across District of Columbia, Massachusetts, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.